Published in Bull World Health Organ on January 01, 1969
Evaluation of rapid radiometric method for drug susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol (1981) 9.67
Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol (2007) 5.03
Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2002) 4.10
Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol (1970) 3.65
Evaluation of the INNO-LiPA Rif. TB assay, a reverse hybridization assay for the simultaneous detection of Mycobacterium tuberculosis complex and its resistance to rifampin. Antimicrob Agents Chemother (1997) 3.55
Spread of drug-resistant pulmonary tuberculosis in Estonia. J Clin Microbiol (2001) 3.12
Mycobacterium tuberculosis strains with highly discordant rifampin susceptibility test results. J Clin Microbiol (2009) 3.08
Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother (1993) 2.97
Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis. J Clin Microbiol (2006) 2.88
Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol (2009) 2.75
Interlaboratory drug susceptibility testing of Mycobacterium tuberculosis by a radiometric procedure and two conventional methods. J Clin Microbiol (1985) 2.68
Selective Kirchner medium in the culture of specimens other than sputum for mycobacteria. J Clin Pathol (1983) 2.61
Ethambutol MICs and MBCs for Mycobacterium avium complex and Mycobacterium tuberculosis. Antimicrob Agents Chemother (1986) 2.48
ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother (2003) 2.31
Molecular characterization of rifampin-resistant isolates of Mycobacterium tuberculosis from Hungary by DNA sequencing and the line probe assay. J Clin Microbiol (2001) 2.21
Mixed infection and clonal representativeness of a single sputum sample in tuberculosis patients from a penitentiary hospital in Georgia. Respir Res (2006) 2.15
Phenotypic characterization of pncA mutants of Mycobacterium tuberculosis. Antimicrob Agents Chemother (2000) 2.15
Rates of drug resistance and risk factor analysis in civilian and prison patients with tuberculosis in Samara Region, Russia. Thorax (2005) 2.09
Conventional and radiometric drug susceptibility testing of Mycobacterium tuberculosis complex. J Clin Microbiol (1983) 2.08
Genotypic and phenotypic heterogeneity among Mycobacterium tuberculosis isolates from pulmonary tuberculosis patients. J Clin Microbiol (2004) 2.06
Evaluation of tuberculosis transmission in a community by 1 year of systematic typing of Mycobacterium tuberculosis clinical isolates. J Clin Microbiol (1996) 2.03
Current perspectives on drug susceptibility testing of Mycobacterium tuberculosis complex: the automated nonradiometric systems. J Clin Microbiol (2006) 2.00
Resazurin microtiter assay plate testing of Mycobacterium tuberculosis susceptibilities to second-line drugs: rapid, simple, and inexpensive method. Antimicrob Agents Chemother (2003) 1.93
Transmission of MDR and XDR tuberculosis in Shanghai, China. PLoS One (2009) 1.93
Comparison of DNA fingerprint patterns of isolates of Mycobacterium africanum from east and west Africa. J Clin Microbiol (1997) 1.88
Outcomes after chemotherapy with WHO category II regimen in a population with high prevalence of drug resistant tuberculosis. PLoS One (2009) 1.87
Evaluation of mycobacteria growth indicator tube for direct and indirect drug susceptibility testing of Mycobacterium tuberculosis from respiratory specimens in a Siberian prison hospital. J Clin Microbiol (2001) 1.85
Evaluation of the BACTEC radiometric method for detection of 1% resistant populations of Mycobacterium tuberculosis. J Clin Microbiol (1985) 1.85
Genetic and phenotypic characterization of drug-resistant Mycobacterium tuberculosis isolates in Hong Kong. J Antimicrob Chemother (2007) 1.78
Phenotypic and molecular characterization of Mycobacterium tuberculosis isolates resistant to both isoniazid and ethambutol. Antimicrob Agents Chemother (2005) 1.75
Drug susceptibility testing of Mycobacterium tuberculosis complex by use of a high-throughput, reproducible, absolute concentration method. J Clin Microbiol (2007) 1.65
Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother (2004) 1.62
A comparative lipidomics platform for chemotaxonomic analysis of Mycobacterium tuberculosis. Chem Biol (2011) 1.56
Mutations in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis isolates from Brazil. J Clin Microbiol (2000) 1.54
Clinical and microbiological features of HIV-associated tuberculous meningitis in Vietnamese adults. PLoS One (2008) 1.51
Short course chemotherapy for tuberculous lymphadenitis in children. BMJ (1990) 1.51
Correlations of mutations in katG, oxyR-ahpC and inhA genes and in vitro susceptibility in Mycobacterium tuberculosis clinical strains segregated by spoligotype families from tuberculosis prevalent countries in South America. BMC Microbiol (2009) 1.50
Genetic diversity of Mycobacterium tuberculosis isolates from a tertiary care tuberculosis hospital in South Korea. J Clin Microbiol (2009) 1.49
Extensively drug-resistant Mycobacterium tuberculosis, India. Emerg Infect Dis (2007) 1.48
Outcome of standardized treatment for patients with MDR-TB from Tamil Nadu, India. Indian J Med Res (2011) 1.46
Newly developed primers for comprehensive amplification of the rpoB gene and detection of rifampin resistance in Mycobacterium tuberculosis. J Clin Microbiol (2006) 1.45
Polymorphisms associated with resistance and cross-resistance to aminoglycosides and capreomycin in Mycobacterium tuberculosis isolates from South Korean Patients with drug-resistant tuberculosis. J Clin Microbiol (2009) 1.43
MIC as a quantitative measurement of the susceptibility of Mycobacterium avium strains to seven antituberculosis drugs. Antimicrob Agents Chemother (1988) 1.42
Tuberculosis: drug resistance, fitness, and strategies for global control. Eur J Pediatr (2007) 1.41
Kanamycin susceptibility testing of Mycobacterium tuberculosis using Mycobacterium Growth Indicator Tube and a colorimetric method. Antimicrob Agents Chemother (2001) 1.40
Evaluation of Direct Colorimetric MTT Assay for Rapid Detection of Rifampicin and Isoniazid Resistance in Mycobacterium tuberculosis. PLoS One (2016) 1.39
Rapid antibiotic-resistance predictions from genome sequence data for Staphylococcus aureus and Mycobacterium tuberculosis. Nat Commun (2015) 1.34
Direct detection of Mycobacterium tuberculosis complex DNA and rifampin resistance in clinical specimens from tuberculosis patients by line probe assay. J Clin Microbiol (2006) 1.34
A random sample survey of initial drug resistance among tuberculosis cases in Latin America. Bull World Health Organ (1994) 1.33
Discordance across several methods for drug susceptibility testing of drug-resistant Mycobacterium tuberculosis isolates in a single laboratory. J Clin Microbiol (2013) 1.33
Genotypic diversity and drug susceptibility patterns among M. tuberculosis complex isolates from South-Western Ghana. PLoS One (2011) 1.31
Pulmonary tuberculosis and drug resistance in Dhaka central jail, the largest prison in Bangladesh. PLoS One (2010) 1.31
Mutations in gidB confer low-level streptomycin resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2011) 1.29
Multidrug-resistant Mycobacterium tuberculosis in HIV-infected persons, Peru. Emerg Infect Dis (2003) 1.29
Validation of the use of Middlebrook 7H10 agar, BACTEC MGIT 960, and BACTEC 460 12B media for testing the susceptibility of Mycobacterium tuberculosis to levofloxacin. J Clin Microbiol (2004) 1.27
Characterization of a distinct group of slowly growing mycobacteria by biochemical tests and lipid analyses. J Clin Microbiol (1992) 1.25
Can molecular methods detect 1% isoniazid resistance in Mycobacterium tuberculosis? J Clin Microbiol (2013) 1.25
Molecular characterisation of Mycobacterium tuberculosis isolates in the First National Survey of Anti-tuberculosis Drug Resistance from Venezuela. BMC Microbiol (2006) 1.24
Multidrug-resistant tuberculosis in Russia: clinical characteristics, analysis of second-line drug resistance and development of standardized therapy. Eur J Clin Microbiol Infect Dis (2005) 1.21
Philip Ellman lecture. The modern management and therapy of pulmonary tuberculosis. Proc R Soc Med (1977) 1.19
Comparative evaluation of Löwenstein-Jensen proportion method, BacT/ALERT 3D system, and enzymatic pyrazinamidase assay for pyrazinamide susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol (2006) 1.16
Rifampin heteroresistance in Mycobacterium tuberculosis cultures as detected by phenotypic and genotypic drug susceptibility test methods. J Clin Microbiol (2013) 1.16
Mutations in katG, inhA, and ahpC genes of Brazilian isoniazid-resistant isolates of Mycobacterium tuberculosis. J Clin Microbiol (2003) 1.15
Evaluation of molecular-Beacon, TaqMan, and fluorescence resonance energy transfer probes for detection of antibiotic resistance-conferring single nucleotide polymorphisms in mixed Mycobacterium tuberculosis DNA extracts. J Clin Microbiol (2006) 1.14
Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice. Am J Respir Crit Care Med (2011) 1.13
Impact of introducing the line probe assay on time to treatment initiation of MDR-TB in Delhi, India. PLoS One (2014) 1.11
Determination of drug resistance of Mycobacterium tuberculosis cultures. Appl Microbiol (1971) 1.11
Colorimetric detection of multidrug-resistant or extensively drug-resistant tuberculosis by use of malachite green indicator dye. J Clin Microbiol (2007) 1.09
Prevalence of fluoroquinolone resistance among tuberculosis patients in Shanghai, China. Antimicrob Agents Chemother (2009) 1.09
Selection of mutations to detect multidrug-resistant Mycobacterium tuberculosis strains in Shanghai, China. Antimicrob Agents Chemother (2009) 1.08
Tuberculosis in the developing world: recent advances in diagnosis with special consideration of extensively drug-resistant tuberculosis. Curr Opin Infect Dis (2008) 1.07
Rapid detection of isoniazid, rifampin, and ofloxacin resistance in Mycobacterium tuberculosis clinical isolates using high-resolution melting analysis. J Clin Microbiol (2011) 1.06
Rapid and inexpensive detection of multidrug-resistant Mycobacterium tuberculosis with the nitrate reductase assay using liquid medium and direct application to sputum samples. J Clin Microbiol (2008) 1.05
Prevalence and Drug Resistance Patterns of Mycobacterium tuberculosis among New Smear Positive Pulmonary Tuberculosis Patients in Eastern Ethiopia. Tuberc Res Treat (2014) 1.05
Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients. PLoS One (2013) 1.04
Clinical evaluation of the microscopic observation drug susceptibility assay for detection of Mycobacterium tuberculosis resistance to isoniazid or rifampin. J Clin Microbiol (2007) 1.03
Rapid detection of ofloxacin resistance in Mycobacterium tuberculosis by two low-cost colorimetric methods: resazurin and nitrate reductase assays. J Clin Microbiol (2005) 1.02
TB incidence and characteristics in the remote gulf province of Papua New Guinea: a prospective study. BMC Infect Dis (2014) 1.01
Prevalence and genetic characterization of second-line drug-resistant and extensively drug-resistant Mycobacterium tuberculosis in Rural China. Antimicrob Agents Chemother (2013) 1.00
Mixed infections of Mycobacterium tuberculosis in tuberculosis patients in Shanghai, China. Tuberculosis (Edinb) (2008) 1.00
Reduced NK activity correlates with active disease in HIV- patients with multidrug-resistant pulmonary tuberculosis. Clin Exp Immunol (1994) 0.99
Low Occurrence of Tuberculosis Drug Resistance among Pulmonary Tuberculosis Patients from an Urban Setting, with a Long-Running DOTS Program in Zambia. Tuberc Res Treat (2010) 0.98
Resistance to rifampicin and isoniazid in strains of Mycobacterium tuberculosis. J Clin Pathol (1981) 0.98
A multi-site validation in India of the line probe assay for the rapid diagnosis of multi-drug resistant tuberculosis directly from sputum specimens. PLoS One (2014) 0.98
Temperature-mediated heteroduplex analysis for detection of pncA mutations associated with pyrazinamide resistance and differentiation between Mycobacterium tuberculosis and Mycobacterium bovis by denaturing high- performance liquid chromatography. J Clin Microbiol (2004) 0.97
Drug-resistant tuberculosis in a tertiary referral teaching hospital of Korea. Korean J Intern Med (2001) 0.97
Performance of the GenoType MTBDRplus assay directly on sputum specimens from Brazilian patients with tuberculosis treatment failure or relapse. J Clin Microbiol (2013) 0.96
Comparison of intermittent ethambutol with rifampicin-based regimens in HIV-infected adults with PTB, Kampala. Int J Tuberc Lung Dis (2006) 0.96
IS6110-restriction fragment length polymorphism and spoligotyping analysis of Mycobacterium tuberculosis clinical isolates for investigating epidemiologic distribution in Korea. J Korean Med Sci (2010) 0.94
Evaluation of the invader assay, a linear signal amplification method, for identification of mutations associated with resistance to rifampin and isoniazid in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2000) 0.94
Evidence that rifampicin can be used safely for non-tuberculous diseases. Thorax (1980) 0.94
Distribution of spoligotyping defined genotypic lineages among drug-resistant Mycobacterium tuberculosis complex clinical isolates in Ankara, Turkey. PLoS One (2012) 0.93
Significant Effects of Oral Phenylbutyrate and Vitamin D3 Adjunctive Therapy in Pulmonary Tuberculosis: A Randomized Controlled Trial. PLoS One (2015) 0.93
Draft Genome Sequence of a Clinical Isolate of Multidrug-Resistant Mycobacterium tuberculosis East African Indian Strain OSDD271. Genome Announc (2013) 0.93
Novel katG mutations causing isoniazid resistance in clinical M. tuberculosis isolates. Emerg Microbes Infect (2015) 0.93
Epidemiology of tuberculosis in an urban slum of Dhaka City, Bangladesh. PLoS One (2013) 0.92
Evaluation of direct detection of Mycobacterium tuberculosis rifampin resistance by a nitrate reductase assay applied to sputum samples in Cotonou, Benin. J Clin Microbiol (2007) 0.92
Conventional and molecular epidemiology of tuberculosis in homeless patients in Budapest, Hungary. J Clin Microbiol (2004) 0.92
Proficiency analysis of drug susceptibility testing by national-level tuberculosis reference laboratories from 1995 to 2003. J Clin Microbiol (2007) 0.92
Prevalence and risk factors for adult pulmonary tuberculosis in a metropolitan city of South India. PLoS One (2015) 0.92
MYCOBACTERIA: LABORATORY METHODS FOR TESTING DRUG SENSITIVITY AND RESISTANCE. Bull World Health Organ (1963) 9.26
[Measurement of sensitivity of the tuberculous bacillus to antibacillary drugs by the method of proportions. Methodology, resistance criteria, results and interpretation]. Rev Tuberc Pneumol (Paris) (1963) 5.58
Present aspects of bacterial resistance in tuberculosis. Am Rev Respir Dis (1965) 3.90
Identification of tubercle bacilli from Indian patients with pulmonary tuberculosis. Bull World Health Organ (1961) 2.76
[Contribution to the elimination of discrepancies in the determination of tubercle bacilli resistant to streptomycin]. Beitr Klin Tuberk Spezif Tuberkuloseforsch (1962) 2.43
[Current data on primary resistance in pulmonary tuberculosis in adults in France. 2d survey of the Centre d'Etudes sur la Resistance Primaire: 1965-1966]. Rev Tuberc Pneumol (Paris) (1967) 2.34
Towards an international standardization of resistance tests on mycobacteria. Scand J Respir Dis (1968) 2.31
A selective oleic acid albumin agar medium for tubercle bacilli. J Med Microbiol (1972) 6.78
Antigenic diversity of Mycobacterium tuberculosis and Mycobacterium bovis detected by means of monoclonal antibodies. Lancet (1981) 6.01
The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis (1980) 4.69
Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis (1999) 4.52
Present aspects of bacterial resistance in tuberculosis. Am Rev Respir Dis (1965) 3.90
A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis (2008) 3.77
The action of antituberculosis drugs in short-course chemotherapy. Tubercle (1985) 3.69
Changes in annual tuberculosis notification rates between 1978/79 and 1983 for the population of Indian subcontinent ethnic origin resident in England. J Epidemiol Community Health (1986) 3.48
Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis (1986) 3.46
The variability of measurements of casual blood pressure. II. Survey experience. Clin Sci (1966) 3.19
Timing of relapse in short-course chemotherapy trials for tuberculosis. Int J Tuberc Lung Dis (2010) 3.07
Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis (1993) 3.01
Deaths occurring in newly notified patients with pulmonary tuberculosis in England and Wales. Br J Dis Chest (1984) 2.71
Selective Kirchner medium in the culture of specimens other than sputum for mycobacteria. J Clin Pathol (1983) 2.61
Sulphadimidine acetylation test for classification of patients as slow or rapid inactivators of isoniazid. Br Med J (1970) 2.61
Short-course chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis (1975) 2.59
The use of murine monoclonal antibodies without purification of antigen in the serodiagnosis of tuberculosis. J Immunol Methods (1982) 2.57
Quality control in tuberculosis bacteriology. 1. Laboratory studies on isolated positive cultures and the efficiency of direct smear examination. Tubercle (1980) 2.57
Ambiguities and inaccuracies in the notification system for tuberculosis in England and Wales. Community Med (1981) 2.55
[Current data on primary resistance in pulmonary tuberculosis in adults in France. 2d survey of the Centre d'Etudes sur la Resistance Primaire: 1965-1966]. Rev Tuberc Pneumol (Paris) (1967) 2.34
Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis. Am Rev Respir Dis (1981) 2.31
Some comparative aspects of rifampicin and isoniazid. Tubercle (1968) 2.28
Selective media in the isolation of tubercle bacilli from tissues. J Clin Pathol (1973) 2.17
Conservation. High value and long life--double jeopardy for tunas and billfishes. Science (2011) 2.14
The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment. J Antimicrob Chemother (1993) 2.12
Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Ten-year follow-up. Lancet (1973) 2.12
Whither short-course chemotherapy? Br J Dis Chest (1981) 2.07
A 5-year study of patients with pulmonary tuberculosis in a concurrent comparison of home and sanatorium treatment for one year with isoniazid plus PAS. Bull World Health Organ (1966) 2.04
Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide. J Bacteriol (2000) 2.03
Basic mechanisms of chemotherapy. Chest (1979) 2.01
Controlled clinical trial of complete open surgical drainage and of prednisolone in treatment of tuberculous pericardial effusion in Transkei. Lancet (1988) 1.99
Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide. Antimicrob Agents Chemother (1996) 1.97
Application of DNA fingerprinting with IS986 to sequential mycobacterial isolates obtained from pulmonary tuberculosis patients in Hong Kong before, during and after short-course chemotherapy. Tuber Lung Dis (1993) 1.94
Bone and joint tuberculosis. A survey of notifications in England and Wales. J Bone Joint Surg Br (1984) 1.93
A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. J Antimicrob Chemother (2000) 1.90
A computer-assisted bacteriology reporting and information system. J Clin Pathol (1978) 1.86
[Tuberculosis bacilli of the African type: preliminary note]. Rev Tuberc Pneumol (Paris) (1968) 1.85
A controlled study of the influence of segregation of tuberculous patients for one year on the attack rate of tuberculosis in a 5-year period in close family contacts in South India. Bull World Health Organ (1966) 1.82
The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis. Am J Respir Crit Care Med (1997) 1.76
[Comparative study of the Ziehl-Neelsen and fluorescent microscopy methods of staining tubercle bacilli of excised pulmonary tissue]. Arch Inst Pasteur Alger (1971) 1.73
Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures. Int J Tuberc Lung Dis (2002) 1.73
Synthesis and antituberculosis activity of thiocarboxamide derivatives of Schiff bases. J Pharm Sci (1977) 1.70
An effective method of RNA extraction from bacteria refractory to disruption, including mycobacteria. Nucleic Acids Res (1997) 1.69
Compliance of patients and physicians: experience and lessons from tuberculosis-I. Br Med J (Clin Res Ed) (1983) 1.68
The chemotherapy of pulmonary tuberculosis: a review. Chest (1979) 1.65
Primary drug resistance in pulmonary tuberculosis in Great Britain: second national survey, 1963. Tubercle (1966) 1.65
Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst (1999) 1.63
Side effects of intermittent rifampicin. Br Med J (1971) 1.59
Activity in vitro of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages. Am Rev Respir Dis (1992) 1.56
General considerations in the choice and management of regimens of chemotherapy for pulmonary tuberculosis. Bull Int Union Tuberc (1972) 1.56
The correlation of bacteriophage types of Mycobacterium tuberculosis with guinea-pig virulence and in vitro-indicators of virulence. J Gen Microbiol (1978) 1.55
Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility testing with Mycobacterium tuberculosis. J Clin Microbiol (2000) 1.51
Bactericidal activity of streptomycin, isoniazid, rifampin, ethambutol, and pyrazinamide alone and in combination against Mycobacterium Tuberculosis. Am Rev Respir Dis (1977) 1.50
Controlled trial of prednisolone as adjuvant in treatment of tuberculous constrictive pericarditis in Transkei. Lancet (1987) 1.49
Protein synthesis is shutdown in dormant Mycobacterium tuberculosis and is reversed by oxygen or heat shock. FEMS Microbiol Lett (1998) 1.48
Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother (1996) 1.48
Bioavailability of rifampin in experimental murine tuberculosis. Antimicrob Agents Chemother (1992) 1.48
Suitability of rifampicin for intermittent administration in the treatment of tuberculosis. Tubercle (1970) 1.45
Bioavailability of Chinese rifapentine during a clinical trial in Hong Kong. Int J Tuberc Lung Dis (1997) 1.44
Suitability of isoniazid and ethambutol for intermittent administration in the treatment of tuberculosis. Tubercle (1968) 1.43
Observations in vitro on the suitability of pyrazinamide for intermittent chemotherapy of tuberculosis. Tubercle (1970) 1.41
Drug resistance in mycobacteria. Br Med Bull (1984) 1.40
Adverse reactions to daily and intermittent rifampicin regimens for pulmonary tuberculosis in Hong Kong. Br Med J (1972) 1.40
Rifabutin in the treatment of newly diagnosed pulmonary tuberculosis. Tuber Lung Dis (1995) 1.39
Tuberculosis in Scotland: a national sample survey (1968-70). 2. A two-year follow-up of newly-diagnosed respiratory tuberculosis notified in 1968. Tubercle (1976) 1.39
Contributions to the Pathology of the Glandular Structures of the Stomach. Med Chir Trans (1858) 1.38
HLA typing in the Hong Kong Chest Service/British Medical Research Council study of factors associated with the breakdown to active tuberculosis of inactive pulmonary lesions. Am Rev Respir Dis (1988) 1.38
Analysis and comparison of nucleotide sequences encoding the genes for [NiFe] and [NiFeSe] hydrogenases from Desulfovibrio gigas and Desulfovibrio baculatus. J Bacteriol (1989) 1.38
Compliance of patients and physicians: experience and lessons from tuberculosis-II. Br Med J (Clin Res Ed) (1983) 1.38
Quality control in tuberculosis bacteriology. 2. The origin of isolated positive cultures from the sputum of patients in four studies of short course chemotherapy in Africa. Tubercle (1980) 1.36
In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria. Tubercle (1987) 1.35
Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis. S Afr Med J (1996) 1.34
The diet, physical activity and accommodation of patients with quiescent pulmonary tuberculosis in a poor South Indian community. A four-year follow-up study. Bull World Health Organ (1966) 1.33
The bacterial DNA content of mouse organs in the Cornell model of dormant tuberculosis. Tuber Lung Dis (1995) 1.33
Studies of case-finding for pulmonary tuberculosis in outpatients at 4 district hospitals in Kenya. Tubercle (1985) 1.31
In vitro observations on the suitability of new rifamycins for the intermittent chemotherapy of tuberculosis. Tubercle (1987) 1.30
Laboratory aspects of intermittent drug therapy. Postgrad Med J (1971) 1.28
Metronidazole has no antibacterial effect in Cornell model murine tuberculosis. Int J Tuberc Lung Dis (1998) 1.28
The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med (1997) 1.27
5-year follow-up of cytotoxic chemotherapy as an adjuvant to surgery in carcinoma of the bronchus. Br J Cancer (1976) 1.27
A four-year follow-up of patients with quiescent pulmonary tuberculosis at the end of a year of chemotherapy with twice-weekly isoniazid plus streptomycin or daily isoniazid plus pas. Tubercle (1969) 1.24
A survey of deaths in Hong Kong attributed to tuberculosis. Tubercle (1981) 1.24
Amikacin in the treatment of pulmonary tuberculosis. Tubercle (1983) 1.23
Examination of sputum by smear and culture in case-finding. Bull Int Union Tuberc (1968) 1.23
Geographic distribution of bacteriophage types of Mycobacterium tuberculosis. Am Rev Respir Dis (1969) 1.23
The value of colonoscopy in schistosomal, tuberculous, and amebic colitis. Two-year experience. Dis Colon Rectum (1986) 1.22
[Experimental antitubercular activity of rifampicin, a derivative of rifamycin SV]. Rev Tuberc Pneumol (Paris) (1970) 1.21
Bactericidal action of gatifloxacin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother (2005) 1.21
Pulmonary tuberculosis in Scotland: a national sample survey and follow-up (1968-70). 1. The characteristics of the cases notified in 1968. Tubercle (1975) 1.21
Madras study of supervised once-weekly chemotherapy. Bull Int Union Tuberc (1968) 1.21
Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis. Int J Tuberc Lung Dis (2006) 1.20
Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report. Am J Respir Crit Care Med (1998) 1.20
In vitro properties of rifapentine (MDL473) relevant to its use in intermittent chemotherapy of tuberculosis. Tubercle (1987) 1.19